A Study to Evaluate Efficacy and Safety of Tiotropium in Children 6 to 11 Years Old With Moderate Asthma
Condition: Asthma
MeSH terms: Asthma
Intervention: Tiotropium bromide; Tiotropium bromide; Tiotropium bromide; Tiotropium bromide
Intervention description: inhalation solution administered via Respimat in 3 different doses; inhalation solution administered via Respimat in 3 different doses; inhalation solution administered via Respimat in 3 different doses; inhalation solution administered via Respimat in 3 different doses
Intervention MeSH terms: Bromides; Tiotropium Bromide
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment: 101.0
Sex: All
Minimum age: 6 Years
Maximum age: 11 Years
Healthy volunteers: No

Summary:

      The aim of this trial is to select an optimum dose may be selected based on bronchodilator
      efficacy, safety evaluations and pharmacokinetics of tiotropium bromide.
    

Eligibility criteria:

        Inclusion criteria:

        Patients must meet all of the following inclusion criteria to be eligible for enrollment
        into this study:

          1. All patients' parents (or legally accepted caregivers) must sign and date an informed
             consent prior to any study procedures including medication washout and restrictions.
             In addition, an informed assent suitable for this age group has to be obtained from
             patients.

          2. Male or female patients between 6 and 11 years of age (up to 1 day prior to their 12th
             birthday at Visit 1).

          3. All patients must have at least a 6-month history of asthma at the time of enrolment
             into the trial.

          4. All patients must have been on maintenance treatment with inhaled corticosteroids at a
             stable medium dose - a patient is eligible on =200 µg to =400 µg Budesonide DPI or
             equivalent.

          5. All patients must be symptomatic (partly controlled) at Visit 1 (screening) and prior
             to randomisation at Visit 2 as defined by an ACQ mean score of =1.5.

          6. All patients must have a pre-bronchodilator FEV1 =60% and =90% of predicted normal at
             Visit 1. Variation of absolute FEV1 values of Visit 2 (pre-dose) as compared to values
             at Visit 2 (pre-bronchodilator) must be within ± 30%.

          7. All patients must demonstrate an increase in FEV1 of =12% 15 to 30 min. after 200 µg
             salbutamol (albuterol) at Visit 1.

          8. Patients must be able to inhale from the Respimat® inhaler correctly.

          9. Patients must be able to perform all trial related procedures including technically
             acceptable spirometric manoeuvres according to current ATS/ERS standards and the use
             of the electronic diary/peak flow meter.

        Exclusion criteria:

        Patients with any of the following characteristics will not be eligible for entry into this
        study:

          1. Patients with a significant disease other than asthma.

          2. Patients with clinically relevant abnormal screening haematology or blood chemistry
             will be excluded if the abnormality defines a significant disease as defined in
             exclusion criterion 1. For participation in PK sampling, a haemoglobin of less than
             11.3 g/dL will be regarded as exclusion criterion.

          3. Patients with a history of congenital or acquired heart disease, or patients who have
             been hospitalised for cardiac syncope or failure during the past year.

          4. Patients with any unstable or life-threatening cardiac arrhythmia, including cardiac
             arrhythmia requiring intervention (e.g. pacemaker implantation, catheter ablation
             etc.) or a change in drug therapy within the past year.

          5. Patients with a malignancy for which the patient has undergone resection, radiation
             therapy or chemotherapy within the last five years.

          6. Patients with clinically significant lung diseases other than asthma, such as CF, or
             bronchopulmonary dysplasia.

          7. Patients with known active tuberculosis.

          8. Patients who have undergone thoracotomy with pulmonary resection. Patients with a
             history of thoracotomy for other reasons should be evaluated as per exclusion
             criterion No. 1.

          9. Patients who are currently in a pulmonary rehabilitation program or have completed a
             pulmonary rehabilitation program in the 6 weeks prior to the screening visit (Visit
             1).

         10. Patients with known hypersensitivity to anticholinergic drugs, BAC, EDTA or any other
             components of the tiotropium inhalation solution.

         11. Patients with known narrow-angle glaucoma, or any other disease where anticholinergic
             treatment is contraindicated.

         12. Patients with moderate to severe renal impairment, as defined by a creatinine
             clearance <50 mL/min./1.73 m2 BSA, as tiotropium is a predominantly renally excreted
             drug.